Zhancheng Qiu
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Underrecognized cardiovascular complications after hepatectomy: population-level mortality burden from a multicentre population-attributable fraction (PAF) analysis.
Journal: Bioscience trends
Published: August 03, 2026
Clinical and economic outcomes of robotic-assisted, laparoscopic, and open liver resection in BCLC 0/A hepatocellular carcinoma: a nationwide cohort study.
Journal: International journal of surgery (London, England)
Published: June 11, 2025
A novel pathologic scoring system for predicting postoperative recurrence in BCLC stage 0-A hepatocellular carcinoma patients: a nationwide multicenter study.
Journal: Science China. Life sciences
Published: April 05, 2025
Risk factors for hepatocellular carcinoma rupture: multicentre retrospective study.
Journal: BJS open
Published: January 03, 2025
Tenofovir vs Entecavir on the Prognosis of Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma After Liver Resection: The Role of HBsAg Levels.
Journal: Clinical and translational gastroenterology
Published: August 12, 2024
Establishing and Externally Validating a Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score-Based Nomogram for Predicting Early Recurrence in BCLC Stage 0/A Hepatocellular Carcinoma Patients After Radical Liver Resection: A Multi-Center Study.
Journal: Journal of hepatocellular carcinoma
Published: February 24, 2024
The application and prospection of augmented reality in hepato-pancreato-biliary surgery.
Journal: Bioscience trends
Published: June 26, 2023
Nomogram to predict liver surgery-specific complications for hepatocellular carcinoma: A multicenter study.
Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: April 15, 2023
Insurance status impacts survival of hepatocellular carcinoma patients after liver resection.
Journal: Cancer medicine
Published: March 26, 2023
TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial.
Journal: Frontiers in oncology
Published: January 05, 2023
Showing 1-11 of 11
Last Updated: 09/26/2026